Annual EBITDA
-$11.39 M
+$10.03 M+46.83%
December 1, 2023
Summary
- As of February 7, 2025, ADXN annual EBITDA is -$11.39 million, with the most recent change of +$10.03 million (+46.83%) on December 1, 2023.
- During the last 3 years, ADXN annual EBITDA has risen by +$1.85 million (+13.94%).
- ADXN annual EBITDA is now -150.05% below its all-time high of $22.76 million, reached on December 31, 2008.
Performance
ADXN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$1.70 M
-$218.30 K-14.69%
September 1, 2024
Summary
- As of February 7, 2025, ADXN quarterly EBITDA is -$1.70 million, with the most recent change of -$218.30 thousand (-14.69%) on September 1, 2024.
- Over the past year, ADXN quarterly EBITDA has dropped by -$985.10 thousand (-137.05%).
- ADXN quarterly EBITDA is now -437.51% below its all-time high of -$317.00 thousand, reached on March 31, 2023.
Performance
ADXN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$13.70 M
-$985.10 K-7.75%
September 1, 2024
Summary
- As of February 7, 2025, ADXN TTM EBITDA is -$13.70 million, with the most recent change of -$985.10 thousand (-7.75%) on September 1, 2024.
- Over the past year, ADXN TTM EBITDA has dropped by -$8.46 million (-161.38%).
- ADXN TTM EBITDA is now -366.72% below its all-time high of -$2.93 million, reached on March 31, 2019.
Performance
ADXN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ADXN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.8% | -137.1% | -161.4% |
| 3 y3 years | +13.9% | +63.7% | +16.2% |
| 5 y5 years | -639.2% | +51.7% | +4.9% |
ADXN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.8% | -437.5% | +82.5% | -161.4% | +39.0% |
| 5 y | 5-year | at high | +46.8% | -437.5% | +82.5% | -161.4% | +39.0% |
| alltime | all time | -150.1% | +69.1% | -437.5% | +82.5% | -366.7% | +39.0% |
Addex Therapeutics Ltd EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.70 M(+14.7%) | -$13.70 M(+7.8%) |
| Jun 2024 | - | -$1.49 M(+95.5%) | -$12.71 M(+8.4%) |
| Mar 2024 | - | -$760.00 K(-92.2%) | -$11.72 M(+3.9%) |
| Dec 2023 | -$11.39 M(-46.8%) | -$9.75 M(+1255.8%) | -$11.28 M(+115.2%) |
| Sep 2023 | - | -$718.80 K(+45.1%) | -$5.24 M(-39.7%) |
| Jun 2023 | - | -$495.50 K(+56.3%) | -$8.69 M(-44.2%) |
| Mar 2023 | - | -$317.00 K(-91.5%) | -$15.58 M(-27.4%) |
| Dec 2022 | -$21.42 M(+31.0%) | -$3.71 M(-11.0%) | -$21.45 M(-4.4%) |
| Sep 2022 | - | -$4.17 M(-43.6%) | -$22.44 M(+1.6%) |
| Jun 2022 | - | -$7.38 M(+19.3%) | -$22.08 M(+11.9%) |
| Mar 2022 | - | -$6.19 M(+31.7%) | -$19.73 M(+20.7%) |
| Dec 2021 | -$16.35 M(+23.5%) | -$4.70 M(+23.2%) | -$16.34 M(+17.7%) |
| Sep 2021 | - | -$3.81 M(-24.2%) | -$13.88 M(+2.4%) |
| Jun 2021 | - | -$5.03 M(+79.7%) | -$13.55 M(+16.5%) |
| Mar 2021 | - | -$2.80 M(+24.7%) | -$11.63 M(-11.4%) |
| Dec 2020 | -$13.24 M | -$2.24 M(-35.6%) | -$13.13 M(-9.1%) |
| Sep 2020 | - | -$3.48 M(+11.8%) | -$14.45 M(-0.3%) |
| Jun 2020 | - | -$3.11 M(-27.5%) | -$14.50 M(-8.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$4.29 M(+20.4%) | -$15.76 M(+9.4%) |
| Dec 2019 | -$14.41 M(+835.2%) | -$3.57 M(+1.0%) | -$14.40 M(+32.9%) |
| Sep 2019 | - | -$3.53 M(-19.3%) | -$10.84 M(+48.3%) |
| Jun 2019 | - | -$4.37 M(+49.1%) | -$7.31 M(+149.1%) |
| Mar 2019 | - | -$2.93 M | -$2.93 M |
| Dec 2018 | -$1.54 M(-53.5%) | - | - |
| Dec 2017 | -$3.31 M(+5.2%) | - | - |
| Dec 2016 | -$3.15 M(-23.9%) | - | - |
| Dec 2015 | -$4.14 M(+127.2%) | - | - |
| Dec 2014 | -$1.82 M(-87.8%) | - | - |
| Dec 2013 | -$14.89 M(-43.0%) | - | - |
| Dec 2012 | -$26.13 M(-17.7%) | - | - |
| Dec 2011 | -$31.74 M(+8.7%) | - | - |
| Dec 2010 | -$29.19 M(-20.7%) | - | - |
| Dec 2009 | -$36.82 M(-261.8%) | - | - |
| Dec 2008 | $22.76 M(-182.1%) | - | - |
| Dec 2007 | -$27.74 M(+93.0%) | - | - |
| Dec 2006 | -$14.37 M | - | - |
FAQ
- What is Addex Therapeutics Ltd annual EBITDA?
- What is the all time high annual EBITDA for Addex Therapeutics Ltd?
- What is Addex Therapeutics Ltd annual EBITDA year-on-year change?
- What is Addex Therapeutics Ltd quarterly EBITDA?
- What is the all time high quarterly EBITDA for Addex Therapeutics Ltd?
- What is Addex Therapeutics Ltd quarterly EBITDA year-on-year change?
- What is Addex Therapeutics Ltd TTM EBITDA?
- What is the all time high TTM EBITDA for Addex Therapeutics Ltd?
- What is Addex Therapeutics Ltd TTM EBITDA year-on-year change?
What is Addex Therapeutics Ltd annual EBITDA?
The current annual EBITDA of ADXN is -$11.39 M
What is the all time high annual EBITDA for Addex Therapeutics Ltd?
Addex Therapeutics Ltd all-time high annual EBITDA is $22.76 M
What is Addex Therapeutics Ltd annual EBITDA year-on-year change?
Over the past year, ADXN annual EBITDA has changed by +$10.03 M (+46.83%)
What is Addex Therapeutics Ltd quarterly EBITDA?
The current quarterly EBITDA of ADXN is -$1.70 M
What is the all time high quarterly EBITDA for Addex Therapeutics Ltd?
Addex Therapeutics Ltd all-time high quarterly EBITDA is -$317.00 K
What is Addex Therapeutics Ltd quarterly EBITDA year-on-year change?
Over the past year, ADXN quarterly EBITDA has changed by -$985.10 K (-137.05%)
What is Addex Therapeutics Ltd TTM EBITDA?
The current TTM EBITDA of ADXN is -$13.70 M
What is the all time high TTM EBITDA for Addex Therapeutics Ltd?
Addex Therapeutics Ltd all-time high TTM EBITDA is -$2.93 M
What is Addex Therapeutics Ltd TTM EBITDA year-on-year change?
Over the past year, ADXN TTM EBITDA has changed by -$8.46 M (-161.38%)